Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

v2.4.0.6
Share-based compensation
 6 Months Ended
Jan. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 4 – Share-based compensation


The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended
January 31,

 

Six months ended
January 31,

 

 

 

2012

 

2011

 

2012

 

2011

 

 

 

 

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

$

3

 

$

3

 

$

5

 

$

6

 

Research and development

 

 

1

 

 

7

 

 

4

 

 

10

 

Selling, general and administrative

 

 

213

 

 

309

 

 

421

 

 

630

 

 

 

   

 

   

 

   

 

   

 

 

 

$

217

 

$

319

 

$

430

 

$

646

 

 

 

   

 

   

 

   

 

   

 


No excess tax benefits were recognized during the six month periods ended January 31, 2012 and 2011.


Stock option plans


A summary of the activity relating to the Company’s stock option plans for the six month period ended January 31, 2012 is as follows:


 

 

 

 

 

 

 

 

 

 

 

 

 

Options

 

Weighted
Average
Exercise Price

 

Aggregate
Intrinsic Value

 

 

 

 

 

 

 

 

 

Outstanding at July 31, 2011

 

 

785,124

 

$

14.53

 

$

—

 

 

 

 

 

 

 

 

 

   

 

Exercised

 

 

—

 

 

—

 

 

 

 

Cancelled

 

 

(9,549

)

$

17.67

 

 

 

 

 

 

   

 

 

 

 

 

 

 

Outstanding and exercisable at end of period

 

 

775,575

 

$

14.49

 

$

—

 

 

 

   

 

 

 

 

   

 


As of January 31, 2012, there were no unvested stock options.


Restricted Stock Awards


A summary of the activity pursuant to the Company’s restricted stock awards for the six months ended January 31, 2012 is as follows:


 

 

 

 

 

 

 

 

 

 

Awards

 

Weighted
Average
Award Price

 

 

 

 

 

 

 

Unvested at July 31, 2011

 

 

311,952

 

$

4.84

 

Awarded

 

 

133,143

 

$

2.48

 

Vested

 

 

(29,585

)

$

5.15

 

Forfeited

 

 

(3,250

)

$

4.28

 

 

 

   

 

   

 

Unvested at end of period

 

 

412,260

 

$

4.06

 

 

 

   

 

   

 


The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of January 31, 2012, there was approximately $1.0 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of one year.


The total number of shares available for grant as equity awards is 2,685,000 as of January 31, 2012.